Centro Hospitalar do Porto, Serviço de Anestesia
Porto, Porto District, 4099-001, Portugal
NCT Number: NCT01337115
The purpose of this study is to determine if the addition of a sciatic nerve block (SNB) to a continuous femoral nerve block (CFNB) improves post-operative analgesia after knee arthroplasty.
Looking for future studies?
Notify MeAll sexes
Interventional
Not applicable
Porto, Porto District, 4099-001, Portugal
Background: Postoperative pain after total knee replacement /arthroplasty (TKA) is a major concern. It is severe pain in 60% of patients and moderate in 30%. Continuous femoral nerve blocks (CFNB) are considered an excellent choice for regional anesthesia for major knee repair but there are some controversies about the need of supplemental obturator or sciatic nerve blocks for achieving better postoperative analgesia. A recent meta-analysis states there is no sufficient evidence to recommend or discharge these associations.
Objectives: We aim to assess the efficacy of the association of a sciatic nerve block (SNB) and a continuous femoral nerve block (CFNB) for reducing postoperative pain in patients submitted to TKA. Methods: A randomized controlled study on 50 patients submitted to TKA. Control group receives a femoral nerve block with a catheter before general anesthesia is induced and the intervention group gets a similar block plus a single shot SNB before general anesthesia. Both groups start a continuous local anesthetic infusion through femoral catheter after the end of surgery and supplemental oral diclofenac and paracetamol. Pain scores are measured until 24h postoperatively, side effects and patient satisfaction are monitored.
Healthy volunteers accepted: No
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
Exclusion criteria
A single shot sciatic nerve block (SNB) is performed with 25 ml of 0.2% ropivacaine before surgery in addition to an isolated continuous femoral nerve block (CFNB) in the control group
Other names: Peripheral nerve blocks, Local anesthetics, Ropivacaine, Femoral nerve block, Sciatic nerve block
A continuous femoral nerve block is performed for peri-operative analgesia and a bolus of 30 ml of ropivacaine 0.375% is injected before induction of general anesthesia and surgery starts. An infusion of 8ml/h of ropivacaine 0.2% is started in post anesthesia care unit (PACU) and maintained for 48h
Other names: Peripheral nerve blocks, Local anesthetics, Ropivacaine, Femoral nerve block
Time frame: 15-30 min after arrival on post anesthesia care unit (PACU)
Pain scores measured by Visual Analogue Score (VAS) scale at 15-30min after Post anesthesia care unit (PACU) arrival VAS is a 100mm scale to measure pain. 0mm - no pain 100mm - worst possible pain
Time frame: 12h after surgery
VAS pain scores are measured by blinded investigators 12h after surgery .
VAS scale:
0 - no pain 100 - worst possible pain
Time frame: 24h after surgery
VAS pain scores are measured by blinded investigators 24h after surgery .
VAS scale:
0 - no pain 100 - worst possible pain
Time frame: 1 month after surgery
Satisfaction with the anesthesia technique using a categorical scale with three levels:
Bad Reasonable Good/Very Good A Fisher's Exact test is made to asses any differences in the distribution of patients in each arm to each level of the categorical scale
Centro Hospitalar do Porto
Other
Effect of a Single Shot Sciatic Nerve Block (SNB) Combined With a Continuous Femoral Block (CFNB) on Pain Scores After Knee Arthroplasty. A Randomized Controlled Trial
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT06860100
Cardiovascular Diseases, Digestive System Diseases
Van, Tuşba, Turkey (Türkiye)
View Trial DetailsNCT07724678
Agnosia, Breast Cancer
Altındağ, Ankara, Turkey (Türkiye)
View Trial DetailsNCT07720999
Dental Caries, Neurologic Manifestations
Cairo, Cairo Governorate, Egypt
View Trial DetailsNCT07718360
Cesarean Section Pain, Neurologic Manifestations
Islamabad, Federal Capital Territory, Pakistan
View Trial Details